Empire Financial Management Company LLC Buys 2,919 Shares of Eli Lilly and Company $LLY

Key Points

• Empire Financial Management increased its Eli Lilly position by 30.9% in the first quarter, buying 2,919 shares for a total of 12,369 shares valued at approximately $11.4 million. Institutional investors collectively own 82.53% of LLY.
• Analysts remain broadly bullish, with a consensus rating of “Moderate Buy” and an average price target of $1,283.64. Recent target increases include Royal Bank of Canada’s $1,500 objective and Jefferies’ $1,350 target.
• Lilly reported strong quarterly performance, including $19.8 billion in revenue, up 55.5% year over year, and EPS of $8.55 versus the $6.97 consensus estimate. The company also declared a quarterly dividend of $1.73 per share, equivalent to a 0.6% annual yield.

Empire Financial Management Company LLC lifted its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 30.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,369 shares of the company's stock after buying an additional 2,919 shares during the quarter. Eli Lilly and Company comprises approximately 2.6% of Empire Financial Management Company LLC's holdings, making the stock its 5th largest position. Empire Financial Management Company LLC's holdings in Eli Lilly and Company were worth $11,377,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of LLY. Norges Bank bought a new position in Eli Lilly and Company in the 4th quarter worth $12,976,634,000. J. Stern & Co. LLP boosted its holdings in Eli Lilly and Company by 46,191.3% during the fourth quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company's stock valued at $4,047,245,000 after acquiring an additional 4,038,502 shares during the period. Cardano Risk Management B.V. boosted its holdings in Eli Lilly and Company by 876.1% during the fourth quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company's stock valued at $2,552,419,000 after acquiring an additional 2,131,734 shares during the period. Fifth Third Bancorp grew its position in shares of Eli Lilly and Company by 321.3% in the first quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company's stock valued at $1,805,959,000 after purchasing an additional 1,497,423 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Eli Lilly and Company by 10.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company's stock valued at $16,024,022,000 after purchasing an additional 1,432,069 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Jefferies Financial Group increased their price target on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a "buy" rating in a report on Tuesday, June 9th. Royal Bank Of Canada boosted their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an "outperform" rating in a report on Wednesday, July 8th. Leerink Partners increased their target price on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an "outperform" rating in a research note on Thursday, June 25th. Bank of America lifted their target price on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a "buy" rating in a research report on Friday, July 10th. Finally, Guggenheim boosted their price target on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a "buy" rating in a research note on Monday, July 13th. Two analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of "Moderate Buy" and an average price target of $1,283.64.

Eli Lilly and Company Stock Up 2.1%

LLY opened at $1,222.61 on Wednesday. The firm has a market cap of $1.15 trillion, a price-to-earnings ratio of 43.43, a PEG ratio of 1.48 and a beta of 0.51. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The firm's 50-day simple moving average is $1,144.84 and its 200-day simple moving average is $1,041.89. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,249.45.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company had revenue of $19.80 billion during the quarter, compared to analysts' expectations of $17.82 billion. During the same quarter in the previous year, the company posted $3.34 earnings per share. Eli Lilly and Company's quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 35.03 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company's dividend payout ratio is currently 24.58%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts and investors remain optimistic about Lilly’s earnings momentum. The company generated $19.8 billion in first-quarter revenue, up roughly 55.5% year over year, and recent analyst price targets have generally exceeded the current trading level. The median target from 14 analysts is $1,336, with targets as high as $1,500. Eli Lilly Stock Opinions on Growth and AI Ventures
• Positive Sentiment: Lilly’s expanding oncology and newer-medicine portfolio is expected to contribute meaningfully to second-quarter results, supplementing demand for its GLP-1 franchise. This diversification could reduce reliance on weight-loss and diabetes products while supporting long-term revenue growth. Here’s How LLY’s Non-GLP-1 Portfolio Is Poised Ahead of Q2 Earnings
• Positive Sentiment: The company is making a reported $2.8 billion investment aimed at expanding growth beyond GLP-1 drugs. Investors also highlighted Lilly’s investments in artificial-intelligence drug discovery, data infrastructure and potential opportunities in emerging treatment categories. Eli Lilly Just Made a $2.8 Billion Bet That Goes Beyond GLP-1 Drugs
• Neutral Sentiment: Institutional trading was mixed: 2,169 investors added shares in the latest quarter, while 1,653 reduced positions. Several large holders made sizable sales, offset by substantial purchases from other institutions. Social-media commentary also emphasized Lilly’s revenue scale and sustained earnings power, but these discussions are not formal company guidance. Eli Lilly Stock Opinions on Growth and AI Ventures
• Negative Sentiment: Insider activity included one reported open-market sale by an executive involving 2,500 shares. While the transaction is relatively small compared with Lilly’s market value, it provides a modest counterpoint to the otherwise bullish coverage. Eli Lilly Stock Opinions on Growth and AI Ventures

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.